12 December 2022 I Geneva and Doha -- On Universal Health Coverage Day (UHC Day), the World Health Organization (WHO) teams up with international football icons to urge action by governments and people across the world to achieve health for all. UHC ensures that everyone, everywhere can access the support they need to be and stay healthy without being driven into financial hardship.
To mark UHC Day, WHO is launching two new tools: one to help governments design and deliver the right service coverage packages for their populations; and a second to provide people with reliable information to support the everyday decisions they make to protect their health and well-being.
“The World Cup is the greatest prize in football, and the greatest prize in life is good health and well-being,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Health is not a luxury for the rich, but a fundamental human right, and the foundation of peaceful, prosperous and sustainable economies and societies. The tools we are launching today will help governments and individuals to realise that right.”
UHC Day 2022 comes at a critical time when countries across the world are rebuilding from the impacts of the COVID-19 pandemic while facing many other crises such as economic and energy constraints, climate change and conflict.
UHC Day kicks off the countdown to the high-level meeting on UHC which will be held at the United Nations General Assembly in 2023. Heads of State and Government, at the first high-level meeting on UHC in 2019, affirmed that health is a precondition for and an outcome and indicator of the social, economic and environmental dimensions of sustainable development. They strongly recommitted to achieve UHC by 2030 by scaling up the global effort to build a healthier world for all. The 2023 meeting is an opportunity to take stock of progress and galvanize political support and global action towards achieving UHC targets.
On the eve of the semi-finals of the FIFA World Cup 2022™, WHO and its Goodwill Ambassador for Sport and Health, football legend Didier Drogba, led UHC Day celebrations in Doha, Qatar. This formed part of a full day of activities organized by the Education Above All Foundation to put a spotlight on the United Nations Sustainable Development Goal 3: Good health and well-being.
“I found myself in the unusual place where if I had problems on the field, help arrived quickly, and we’ve seen how vital that support can be lately. But off the field, we know, this isn’t always the case,” Didier Drogba said. “Ill-equipped clinics, unsupported health workers, and not enough medicines and vaccines put people’s well-being at risk around the world. Good health needs a team effort, so we need governments to commit to policies that support Universal Health Coverage and give everyone access to what it takes to be healthy. When we team up for health for all, we all win.”
Football enthusiasts of all ages moved to show their support for health for all as electronic dance artist and vocalist, The Mad Stuntman, performed his famous song, “I Like to Move It,” highlighting the importance of staying active and the role of sport in promoting good health and well-being.
Sherrie Silver, Rwandan-British MTV Award winning choreographer, advocate for the International Fund for Agricultural Development of the United Nations, Malaria No More Ambassador and Rwandan development advocate also led the crowd in a dance-off, called the World Cup Workout.
“On Universal Health Coverage Day, let’s all be active and play our part to make health for all our goal, said Alisson Becker, goalkeeper for Brazil and Liverpool, and WHO Goodwill Ambassador for Health Promotion.
Achieving national health goals has been hampered by the lack of a structured approach in designing and delivering a comprehensive package of health services that are tailored to local contexts.
WHO is launching a new tool named the Universal Health Coverage Service Package Delivery and Implementation or UHC SPDI Tool to support countries in designing their unique UHC health service packages. This innovative and practical online tool includes functionalities that will allow national health planners to select from a comprehensive range of health services—spanning promotive, preventive, resuscitative, curative, rehabilitative and palliative services—that people need to reach the highest attainable standard of health and well-being.
The tool is also designed to help identify human resource needs, essential medical products, infrastructure and other elements required for the effective delivery of health services. It also emphasizes first contact primary and emergency care, and highlights a primary health care approach as the basis for strengthening health systems and bringing all sectors under the vision of achieving health for all. The successful implementation of a national health service package will ultimately equip countries to accelerate progress towards UHC.
WHO also launched a digital resource for the public called, “Your life, your health: Tips and information for health and well-being.” It provides people across different life phases with trustworthy health information that they can easily access, understand and use in daily life.
The resource provides basic information, founded on WHO technical guidance, on important topics such as keeping well during pregnancy and after childbirth, or how to be healthy and active in later adulthood. It also provides information on people’s rights and skills related to accessing and using information for health and well-being.
Universal Health Coverage Day (UHC Day) on 12 December is the annual rallying point for advocates to raise their voices and share the stories of the millions of people still waiting for health, call on leaders to make smarter investments in health and remind the world about the imperative of UHC. It is an official United Nations-designated day that marks the anniversary of the unanimous endorsement of UHC in 2012 as an essential priority for international development.
The theme for UHC Day 2022 is “Build the world we want: A healthy future for all.”)
WHO and the State of Qatar have teamed up with FIFA on the Healthy 2022 World Cup project. It aims to ensure the tournament will be a healthy and safe event and that the measures implemented and lessons learned will support the delivery of healthy and safe mega sporting events in the future.
The objectives of the project are to ensure both the delivery and legacy of a healthy and safe FIFA World Cup Qatar 2022™ by setting the event as an impactful, sustainable and lasting model that promotes integration of health, security and well-being for future mega sport events.
The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.
Updated data from the pivotal phase II NP30179 study in people with R/R LBCL showed glofitamab given as a fixed course induced early and durable responses that were maintained beyond the end of treatment. Most patients who had achieved a complete response (CR; a disappearance of all signs of cancer) at the end of treatment experienced durable responses, with a median CR follow-up from end of treatment of 11.5 months (95% confidence interval [CI]: 10.5-16.4). Twelve months after the end of treatment with glofitamab, 61% of patients (n=37/61) maintained a CR, 92.6% remained progression-free and only one patient (n=1/44) experienced disease progression.
Simultaneously, an earlier data cut from the phase II NP30179 study in R/R diffuse large B-cell lymphoma (DLBCL) was published online in NEJM.2
Data from this pivotal phase II study have been submitted for review to the European Medicines Agency, and submissions to additional health authorities worldwide, including the U.S. Food and Drug Administration (FDA), are ongoing.
An updated analysis from the pivotal phase II GO29781 study of Lunsumio in people with R/R FL who had received two or more prior therapies showed 60.0% (n=54/90; 95% CI: 49.1–70.2) achieved a CR and 77.8% (95% CI: 67.8–85.9) achieved an objective response (a CR or a partial response, a decrease in the amount of cancer in their body) at a median follow-up of 28.3 months. After 24 months of achieving a CR, 62.7% of patients remained in remission (95% CI: 37.7–87.7). Overall, 48.3% of patients remained progression-free (95% CI: 36.2-60.3). The median duration of response, median duration of CR, and median progression-free survival were not reached. Safety was consistent with the previous analysis of study data, with no new cytokine release syndrome (CRS) events or Grade 3 or higher adverse events (AEs) reported. CRS events were experienced by 44% of patients, and were predominately low grade and during cycle one.3
The European Commission granted conditional marketing authorisation for Lunsumio for the treatment of people with R/R FL who have received at least two prior systemic therapies in June 2022, making it the first and only fixed-duration bispecific antibody to be approved in Europe for lymphoma. Lunsumio is under Priority Review with the FDA, with a decision expected by 29 December 2022.
Roche continues to evaluate Lunsumio and glofitamab as part of its commitment to providing off-the-shelf therapies for people with lymphomas that can meet their diverse needs, including fixed-duration treatment options. Additional data presented at ASH 2022 include the following:
A subcutaneous (SC) formulation of Lunsumio (administered as an injection given under the skin) demonstrated comparable efficacy with the intravenous formulation and a manageable safety profile in people with R/R non-Hodgkin lymphoma (NHL). The most common AEs were injection site reactions (60.9%; n=53/87) and CRS events (27.6%; n=24/87), which were all Grade 1 or 2. These findings suggest that a SC formulation of Lunsumio may offer patients a treatment option that could reduce their time spent in treatment centres.
Updated results from the phase I/II G050554 study of Lunsumio monotherapy in elderly/unfit patients with previously untreated DLBCL and additional analyses from the phase I/II G040516 study of Lunsumio in combination with Polivy® (polatuzumab vedotin) in heavily pre-treated people with DLBCL continued to show promising efficacy and manageable safety, highlighting the potential of Lunsumio in these patient populations.
Results from the phase I/II NP30179 study evaluating glofitamab as a monotherapy following pre-treatment with Gazyva®/Gazyvaro® (obinutuzumab) in patients with heavily pre-treated R/R mantle cell lymphoma continued to show early, high and durable response rates in this difficult-to-treat disease. After a median follow-up of eight months, the overall response rate (ORR) was 83.8%, with the majority of patients showing durable complete responses at the data cut off (74.1%; n=20/27). The most common AE was CRS (75.5%; n=28/37), with the majority low grade.
Data from the safety and expansion cohorts of the phase Ib NP40126 study evaluating glofitamab in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with previously untreated DLBCL showed, after a median follow-up of 8.5 months, a best ORR of 92.7% (n=51/55) and a complete metabolic response rate of 72.7% (n=40/55). In the safety cohort, CRS events were all low grade (Grade 1 or 2 [10.7%; n=6/56]), and serious AEs were reported in 18 patients (32.1%).
Both Lunsumio and glofitamab are being investigated as SC formulations and in phase III studies that will expand the understanding of their impact in earlier lines of treatment, with the aim of continuing to address the diverse needs and preferences of people with blood cancers. This includes the confirmatory phase III CELESTIMO study investigating Lunsumio plus lenalidomide as a chemotherapy-free option for patients with R/R FL; the phase III SUNMO study investigating Lunsumio plus Polivy versus MabThera/Rituxan in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R aggressive B-cell NHL who are ineligible for autologous stem cell transplant (ASCT); and the phase III STARGLO study evaluating glofitamab in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera/Rituxan in combination with GemOx in patients with R/R DLBCL who are ineligible for ASCT.
Glofitamab is an investigational CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells. Glofitamab was designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T-cells, a type of immune cell, and two regions that bind to CD20, a protein on B-cells, which can be healthy or malignant. This dual-targeting brings the T-cell in close proximity to the B-cell, activating the release of cancer cell-killing proteins from the T-cell. A robust clinical development program for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines for the treatment of people with B-cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma and other blood cancers.
Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual-targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. A robust clinical development programme for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers.
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 20 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab) and Lunsumio® (mosunetuzumab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibodies glofitamab, targeting both CD20 and CD3, cevostamab, targeting both FcRH5 and CD3, Tecentriq® (atezolizumab), a monoclonal antibody designed to bind with PD-L1, and crovalimab, an anti-C5 antibody engineered to optimise complement inhibition. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan